# US 2016/0237048 A1 · Phenothiazine diaminium salts and their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0237048 A1
- Document ID: US20160237048A1
- Status: Published application
- Kind: A1
- Application number: 15/056,610
- Filed: 2016-02-29
- Published: 2016-08-18
- Earliest claimed: 2011-02-11
- Assignees: WisTa Laboratories Ltd.
- Applicants: WisTa Laboratories Ltd.
- Inventors: COLIN MARSHALL; Scott Clunas; John Mervyn David Storey; James Peter Sinclair; Thomas Craven Baddeley; Ahtsham Ishaq; Michael Simpson; Craig Williamson; Barry Alan Wood; Claude Michel Wischik; Charles Robert Harrington; Janet Elizabeth Rickard; David Horsley; Yin Sze Loh; Karrar Ahmad Khan; Christopher Paul Larch
- Web page: https://patentgrep.com/patent/US20160237048A1

## CPC

- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2095: {Tabletting processes}
- A61P 17/00: Drugs for dermatological disorders
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- A61P 33/00: Antiparasitic agents
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 33/06: Antimalarials
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 279/20: with hydrogen atoms directly attached to the ring nitrogen atom
- A61K 9/2893: {Tablet coating processes (mechanical aspects A61J3/06)}
- A61L 2/084: Visible light
- A61L 2103/05: Living organisms or biological materials
- C07C 303/32: of salts of sulfonic acids
- C07C 309/04: containing only one sulfo group
- C07C 309/05: containing at least two sulfo groups bound to the carbon skeleton
- C07C 309/30: of six-membered aromatic rings substituted by alkyl groups
- C07C 309/35: Naphthalene sulfonic acids
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.

## Claims

### Claim 1

A compound selected from compounds of general formula (I):
wherein:
each of R1 and R9 is independently selected from: —H, C1-4alkyl, C2-4alkenyl, and halogenated C1-4alkyl;
each of R3NA and R3NB is independently selected from: —H, C1-4alkyl, C2-4alkenyl, and halogenated C1-4alkyl;
each of R7NA and R7NB is independently selected from: —H, C1-4alkyl, C2-4alkenyl, and halogenated C1-4alkyl;
and wherein:
each of RA and RB is independently selected from:
C1-4alkyl, halogenated C1-4alkyl, and C6-10aryl;
or
RA and RB are linked to form a group selected from:
C1-6 alkylene and C6-10 arylene;
and pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

A compound according to claim 1 wherein each of RA and RB is independently C1-4alkyl.

### Claim 3 (depends on 1)

A compound according to claim 1 wherein each of RA and RB is independently methyl.

### Claim 4 (depends on 1)

A compound according to claim 1, wherein each of R1 and R9 is independently —H.

### Claim 5 (depends on 1)

A compound according to claim 1. wherein each of R3NA and R3NB and is independently C1-4alkyl.

### Claim 6 (depends on 5)

A compound according to claim 5 wherein each of R3NA and R3NB is independently methyl.

### Claim 7 (depends on 1)

A compound according to claim 1, wherein each of R7NA and R7NB is independently C1-4alkyl.

### Claim 8 (depends on 7)

A compound according to claim 7 wherein each of R7NA and R7NB is independently methyl.

### Claim 9 (depends on 1)

A compound according to claim 1 which is of the following formula:
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

### Claim 10 (depends on 1)

A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.

### Claim 11 (depends on 1)

A process for preparing a pharmaceutical composition comprising admixing a compound according to claim 1 with a pharmaceutically acceptable carrier or diluent.

### Claim 12 (depends on 1)

A method of treatment of a disease of protein aggregation in a subject comprising administering the compound of claim 1 to the subject.

### Claim 13 (depends on 1)

A method of treatment of skin cancer or melanoma; or a viral, bacterial or protozoal disease condition in a subject, comprising administering the compound of claim 1 to the subject.

### Claim 14 (depends on 1)

A method of inactivating a pathogen in a sample, comprising the steps of introducing the compound of claim 1 into the sample, and then exposing the sample to light.

### Claim 15 (depends on 1)

A process for the preparation of a compound according to claim 1 from a N-protected 3,7-diamino-10H-phenothiazine, comprising the steps of:
ring amino deprotection (DP); and
salt formation (SF).
wherein ring amino deprotection (DP) and salt formation (SF) comprise treatment of the N-protected 3,7-diamino-10H-phenothiazine with methanesulfonic acid and water, in an organic solvent, to produce the bis(methanesulfonate) salt.
